RU2010130950A - COMPOSITIONS CONTAINING NEBIVOL - Google Patents
COMPOSITIONS CONTAINING NEBIVOL Download PDFInfo
- Publication number
- RU2010130950A RU2010130950A RU2010130950/15A RU2010130950A RU2010130950A RU 2010130950 A RU2010130950 A RU 2010130950A RU 2010130950/15 A RU2010130950/15 A RU 2010130950/15A RU 2010130950 A RU2010130950 A RU 2010130950A RU 2010130950 A RU2010130950 A RU 2010130950A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- arb
- use according
- hydralazine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 16
- RPTUSVTUFVMDQK-UHFFFAOYSA-N hydrallazine Natural products C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims abstract 10
- 229960002474 hydralazine Drugs 0.000 claims abstract 8
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 claims abstract 6
- -1 hydralazine compound Chemical class 0.000 claims abstract 6
- 229960000619 nebivolol Drugs 0.000 claims abstract 6
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims abstract 4
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 239000002083 C09CA01 - Losartan Substances 0.000 claims abstract 3
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims abstract 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims abstract 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims abstract 3
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims abstract 3
- 239000005480 Olmesartan Substances 0.000 claims abstract 3
- 229960000932 candesartan Drugs 0.000 claims abstract 3
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960004563 eprosartan Drugs 0.000 claims abstract 3
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims abstract 3
- 229960002198 irbesartan Drugs 0.000 claims abstract 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960004773 losartan Drugs 0.000 claims abstract 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960005117 olmesartan Drugs 0.000 claims abstract 3
- 229960004699 valsartan Drugs 0.000 claims abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims abstract 3
- 239000005541 ACE inhibitor Substances 0.000 claims abstract 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims abstract 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims abstract 2
- QLTVVOATEHFXLT-UHFFFAOYSA-N Cadralazine Chemical compound CCOC(=O)NNC1=CC=C(N(CC)CC(C)O)N=N1 QLTVVOATEHFXLT-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 241000208011 Digitalis Species 0.000 claims abstract 2
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 claims abstract 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract 2
- 239000003529 anticholesteremic agent Substances 0.000 claims abstract 2
- 229940127226 anticholesterol agent Drugs 0.000 claims abstract 2
- 239000002876 beta blocker Substances 0.000 claims abstract 2
- 229950001730 budralazine Drugs 0.000 claims abstract 2
- DQGFCLJXYFXXIJ-LFIBNONCSA-N budralazine Chemical compound C1=CC=C2C(N/N=C(C)/C=C(C)C)=NN=CC2=C1 DQGFCLJXYFXXIJ-LFIBNONCSA-N 0.000 claims abstract 2
- 229960005211 cadralazine Drugs 0.000 claims abstract 2
- 239000000480 calcium channel blocker Substances 0.000 claims abstract 2
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002877 dihydralazine Drugs 0.000 claims abstract 2
- 239000002934 diuretic Substances 0.000 claims abstract 2
- 230000001882 diuretic effect Effects 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims abstract 2
- ALAXZYHFVBSJKZ-UHFFFAOYSA-N endralazine Chemical compound C1CC=2N=NC(NN)=CC=2CN1C(=O)C1=CC=CC=C1 ALAXZYHFVBSJKZ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002029 endralazine Drugs 0.000 claims abstract 2
- 229960005384 hydralazine hydrochloride Drugs 0.000 claims abstract 2
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960000201 isosorbide dinitrate Drugs 0.000 claims abstract 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims abstract 2
- 229960003827 isosorbide mononitrate Drugs 0.000 claims abstract 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims abstract 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims abstract 2
- KYIAWOXNPBANEW-UHFFFAOYSA-N pildralazine Chemical compound CC(O)CN(C)C1=CC=C(NN)N=N1 KYIAWOXNPBANEW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229950007220 pildralazine Drugs 0.000 claims abstract 2
- 239000011591 potassium Substances 0.000 claims abstract 2
- 229910052700 potassium Inorganic materials 0.000 claims abstract 2
- 229950001089 todralazine Drugs 0.000 claims abstract 2
- 150000004102 olmesartan derivatives Chemical group 0.000 claims 1
- 241000240376 Proteus anguinus Species 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Применение терапевтически безопасного и эффективного количества комбинации из: ! (i) небиволола или его фармацевтической соли; ! (ii) по меньшей мере одного гидралазинового соединения или его фармацевтически приемлемой соли; ! (iii) по меньшей мере одного из изосорбида динитрата и/или изосорбида мононитрата; и ! (iv) необязательно, одного или более соединений, выбранных из группы, состоящей из соединения дигиталиса, диуретика, калия, ингибитора ангиотензин-конвертирующего фермента, бета-адренергического блокатора, средства, понижающего холестерин, блокатора кальциевых каналов, антагониста рецептора ангиотензина II и антагониста эндотелина ! для получения лекарственного средства для улучшения высвобождения NO у чернокожих пациентов, приводящему к снижению смертности, связанной с сердечно-сосудистыми заболеваниями. ! 2. Применение по п.1, где гидралазиновое соединение выбрано из группы, состоящей из будралазина, кадралазина, дигидралазина, эндралазина, гидралазина, пилдралазина и тодралазина, или их фармацевтически приемлемых солей, и их смесей. ! 3. Применение по п.2, где гидралазиновым соединением является гидрохлорид гидралазина. ! 4. Применение по любому из пп.1-3, где небиволол или его фармацевтически приемлемую соль вводят в количестве от 1,25 мг в день до 10 мг в день. ! 5. Применение по п.1, в котором указанная комбинация содержит небиволол или его фармацевтически приемлемую соль и антагонист рецептора ангиотензин II (ARB). ! 6. Применение по п.5, где ARB выбран из группы, состоящей из олмесартана, кандесартана, эпросартана, ирбесартана, лосартана, валсартана и их смесей. ! 7. Применение по п.5, где ARB представляет собой олмес 1. The use of a therapeutically safe and effective amount of a combination of:! (i) nebivolol or a pharmaceutical salt thereof; ! (ii) at least one hydralazine compound or a pharmaceutically acceptable salt thereof; ! (iii) at least one of isosorbide dinitrate and / or isosorbide mononitrate; and! (iv) optionally, one or more compounds selected from the group consisting of a digitalis compound, a diuretic, potassium, an angiotensin converting enzyme inhibitor, a beta adrenergic blocker, a cholesterol lowering agent, a calcium channel blocker, an angiotensin II receptor antagonist and an endothelin antagonist ! to obtain a medicine for improving the release of NO in black patients, leading to a reduction in mortality associated with cardiovascular disease. ! 2. The use according to claim 1, where the hydralazine compound is selected from the group consisting of budralazine, cadralazine, dihydralazine, endralazine, hydralazine, pildralazine and todralazine, or their pharmaceutically acceptable salts, and mixtures thereof. ! 3. The use according to claim 2, where the hydralazine compound is hydralazine hydrochloride. ! 4. The use according to any one of claims 1 to 3, where nebivolol or its pharmaceutically acceptable salt is administered in an amount of from 1.25 mg per day to 10 mg per day. ! 5. The use according to claim 1, wherein said combination comprises nebivolol or a pharmaceutically acceptable salt thereof and an angiotensin II receptor antagonist (ARB). ! 6. The use according to claim 5, where ARB is selected from the group consisting of olmesartan, candesartan, eprosartan, irbesartan, losartan, valsartan and mixtures thereof. ! 7. The use according to claim 5, where ARB is olmes
Claims (12)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/141,235 | 2005-05-31 | ||
| US11/141,235 US7803838B2 (en) | 2004-06-04 | 2005-05-31 | Compositions comprising nebivolol |
| US27256205A | 2005-11-10 | 2005-11-10 | |
| US11/272,562 | 2005-11-10 | ||
| US11/273,992 US7838552B2 (en) | 2004-06-04 | 2005-11-15 | Compositions comprising nebivolol |
| US11/273,992 | 2005-11-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007148414/15A Division RU2441653C2 (en) | 2005-05-31 | 2005-11-16 | Compositions containing nebivolol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010130950A true RU2010130950A (en) | 2012-01-27 |
| RU2593335C2 RU2593335C2 (en) | 2016-08-10 |
Family
ID=41026851
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007148414/15A RU2441653C2 (en) | 2005-05-31 | 2005-11-16 | Compositions containing nebivolol |
| RU2010130950/15A RU2593335C2 (en) | 2005-05-31 | 2010-07-23 | Compositions containing nebivolol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007148414/15A RU2441653C2 (en) | 2005-05-31 | 2005-11-16 | Compositions containing nebivolol |
Country Status (1)
| Country | Link |
|---|---|
| RU (2) | RU2441653C2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2730476C1 (en) * | 2019-12-24 | 2020-08-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Anti-inflammatory ointment for animals |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1175902T3 (en) * | 1996-07-15 | 2005-12-19 | Sankyo Co | Application of CS-866 (olmesartan) to the manufacture of a medicament for the treatment of arteriosclerosis |
| CA2434436A1 (en) * | 2001-01-26 | 2002-08-01 | Teddy Kosoglou | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| WO2002087508A2 (en) * | 2001-05-02 | 2002-11-07 | Nitromed, Inc. | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| EP1635832A2 (en) * | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| EP1635813A4 (en) * | 2003-06-06 | 2009-07-01 | Merck & Co Inc | POLYTHERAPY FOR TREATING DYSLIPIDEMIA |
-
2005
- 2005-11-16 RU RU2007148414/15A patent/RU2441653C2/en active
-
2010
- 2010-07-23 RU RU2010130950/15A patent/RU2593335C2/en active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2441653C2 (en) | 2012-02-10 |
| RU2593335C2 (en) | 2016-08-10 |
| RU2007148414A (en) | 2009-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210261533A1 (en) | 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase | |
| US9592231B2 (en) | Therapy for complications of diabetes | |
| HRP20201605T1 (en) | Pharmaceutical combinations of an angiotensin receptor antagonist and a nep inhibitor | |
| MXPA05008142A (en) | Medicine for prevention of and treatment for arteriosclerosis and hypertension. | |
| NZ598778A (en) | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions | |
| HRP20110969T4 (en) | PIMOBENDAN FOR USE TO REDUCE HEART SIZE IN MAMMALS SUFFERING FROM HEART FAILURE | |
| NZ609344A (en) | Method for treatment of diarrhea-predominant irritable bowel syndrome | |
| US20090221656A1 (en) | Drug Combinations | |
| Balakumar et al. | Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated | |
| RU2008135692A (en) | ORGANIC X-COMPOUND COMBINATION | |
| RU2007132727A (en) | GLUCURONIDED NEBIVOL METABOLITES | |
| RU2010130950A (en) | COMPOSITIONS CONTAINING NEBIVOL | |
| RU2006117790A (en) | APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY | |
| RU2007139928A (en) | BENZIMIDAZOLE DERIVATIVE AND APPLICATION AS ANGIOTENZINE ANTAGONIST | |
| MA30527B1 (en) | GALENIC FORMS ASSOCIATING ALISKIRENE AND HYDROCHLOROTHIAZIDE | |
| EP2919780A1 (en) | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury | |
| JP2018521077A5 (en) | ||
| JPWO2010150921A1 (en) | Treatment for hypertension or normal hypertension | |
| WO2008016171A1 (en) | Prophylactic/therapeutic agent for renal dysfunction | |
| JP5958772B2 (en) | Treatment or prevention drug for kidney damage | |
| Zhi | Discovery of structurally diverse nonsteroidal SPRMs based on a screening hit, 1, 2-dihydro-2, 2, 4-trimethyl-6-phenylquinolinone | |
| WO2007097951A3 (en) | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate | |
| NO20054020L (en) | Medicine for the prevention and treatment of arteriosclerosis and hypertension | |
| RU2007113151A (en) | METHOD FOR LEVELING DYSFUNCTIONS OF THROMBOCYTES IN CONDITIONS OF METABOLIC SYNDROME | |
| DE602006002776D1 (en) | Pharmaceutical composition for the treatment or prevention of cerebral edema |